AKT1 and acute myeloid leukemia: Specifically, PIK3CA mutation, PTEN mutation or inactivation, and AKT hyperactivation have been shown to lead to sustained activation of the PI3K pathway, which has been demonstrated to promote AML and MDS cell proliferation, survival, and anti-apoptosis (94–96).